Compare IMMP & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | SLND |
|---|---|---|
| Founded | 1987 | 1900 |
| Country | Australia | United States |
| Employees | N/A | 1800 |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 64.0M |
| IPO Year | 2012 | N/A |
| Metric | IMMP | SLND |
|---|---|---|
| Price | $0.37 | $0.84 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $5.50 | $4.00 |
| AVG Volume (30 Days) | ★ 634.9K | 77.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $445.09 | N/A |
| Revenue Next Year | N/A | $9.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.65 |
| 52 Week High | $3.53 | $5.34 |
| Indicator | IMMP | SLND |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 33.78 |
| Support Level | $0.35 | $0.65 |
| Resistance Level | $0.39 | $1.46 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 33.66 | 2.52 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.